Placebo multiple dose

DRUG5 trials

Sponsors

Pfizer, Galapagos NV, Dong-A ST Co., Ltd., Cajal Therapeutics Inc.

Conditions

AnemiaChronic Kidney DiseaseHealthyHealthy SubjectsIron Deficiencies

Early Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.

RecruitingNCT07577817

Cajal Therapeutics Inc.Anemia, Chronic Kidney Disease, Iron Deficiencies

Start: 2026-06-01End: 2026-12-30Target: 72Updated: 2026-06-12

Phase 1

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

CompletedNCT02509117

PfizerHealthy Subjects

Start: 2015-07-31End: 2016-07-31Updated: 2018-11-01

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.

CompletedNCT03128606

Galapagos NVHealthy

Start: 2017-03-28End: 2018-02-20Updated: 2018-04-10

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects

CompletedNCT03214614

Galapagos NVHealthy

Start: 2016-11-14End: 2017-08-25Updated: 2017-09-13

A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants

CompletedNCT06391827

Dong-A ST Co., Ltd.Healthy

Start: 2024-05-27End: 2026-01-12Updated: 2026-05-22

Related Papers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects

Journal of Alzheimer s Disease2019-08-1624 citations